Evidence That Long-Term Treatment Prevents Tissue Oxidative Damage in Patients With Inherited Disorders of the

Bianca Gomes Dos Reis1,2, Graziela Schmitt Becker2, Desiree Padilha Marchetti2

  • 1Departamento de Análises Clínicas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Insights

Propionic and methylmalonic acidemias are genetic disorders. Long-term treatment with a restricted protein diet and L-carnitine supplementation reduces oxidative damage markers in affected patients.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Propionic acidemia (PAcidemia) and methylmalonic acidemia (MMAcidemia) are genetic metabolic disorders.
  • These conditions cause severe neonatal metabolic decompensation and encephalopathic episodes.
  • Therapeutic management is critical for patient survival and prognosis.

Purpose of the Study:

  • To investigate the long-term effects of a restricted protein diet with L-carnitine (LC) supplementation on oxidative damage markers.
  • To assess the impact of this therapy on lipid, protein, and DNA/RNA oxidative damage in PAcidemia and MMAcidemia patients.
  • To explore the role of oxidative stress in tissue damage and its modulation by LC therapy.

Main Methods:

  • Measurement of urinary isoprostanes (lipid damage), di-tyrosine (protein damage), and oxidized guanine species (DNA/RNA damage).
  • Quantification of NO products (nitrate plus nitrite) in patients.
  • Comparison of markers in untreated patients, short-term treated patients, and long-term treated patients against controls.

Main Results:

  • Untreated patients showed significantly increased levels of isoprostanes, di-tyrosine, and oxidized guanine species compared to controls.
  • Oxidative damage markers were attenuated after short-term treatment.
  • Markers normalized after prolonged L-carnitine and restricted protein therapy.

Conclusions:

  • Long-standing treatment with a restricted protein diet and L-carnitine protects against oxidative damage in propionate pathway disorders.
  • This therapy likely reduces metabolite accumulation and associated toxicity.
  • Further research is needed to correlate oxidative stress levels with clinical outcomes in affected patients.